# Alembic (NSE: ALEMBICLTD) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/ALEMBICLTD · Pivot · prices to 21 Oct 2026

Alembic (NSE: ALEMBICLTD) closed at ₹92.50 on 21 Oct 2026. With a market capitalisation of ₹2,445 Cr, it ranks 1068th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Real Estate - Development.

At its last close the stock traded at 7.7× trailing earnings, against a return on equity of 13.0% in FY26. Over the past year the share price has fallen 2.8%. Its 52-week range is ₹68.62 (30 Mar 2026) to ₹117.72 (3 Sep 2026); the last close is 21.4% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹150 Cr (+10.6% year on year) and net profit ₹16 Cr (+6.7%), on a standalone basis. Promoters held 70.88% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹92.50 |
| Market cap | ₹2,445 Cr |
| P/E (trailing) | 7.7 |
| ROE | 13.0% (FY26) |
| ROCE | 6.1% (FY26) |
| Debt to equity | 0 |
| 52-week high | ₹117.72 (3 Sep 2026) |
| 52-week low | ₹68.62 (30 Mar 2026) |
| 1-year return | −2.8% |

## Quarterly results (₹ crore, standalone)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q4 FY26 | ₹150 Cr | +10.6% | ₹16 Cr | +6.7% | ₹5.60 |
| Q3 FY26 | ₹141 Cr | +14.9% | ₹19 Cr | +1.0% | ₹6.73 |
| Q2 FY26 | ₹118 Cr | +7.1% | ₹14 Cr | +18.3% | ₹4.83 |
| Q1 FY26 | ₹94 Cr | +12.3% | ₹8 Cr | +79.9% | ₹2.87 |
| Q4 FY25 | ₹135 Cr | +6.6% | ₹15 Cr | +11.1% | ₹5.25 |
| Q3 FY25 | ₹123 Cr | +4.9% | ₹19 Cr | +10.3% | ₹6.66 |
| Q2 FY25 | ₹110 Cr | +10.7% | ₹12 Cr | +72.3% | ₹4.08 |
| Q1 FY25 | ₹84 Cr | +7.6% | ₹5 Cr | −34.1% | ₹1.60 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹222 Cr | ₹145 Cr |
| FY24 | ₹157 Cr | ₹93 Cr |
| FY23 | ₹127 Cr | ₹81 Cr |
| FY22 | ₹78 Cr | ₹86 Cr |
| FY21 | ₹74 Cr | ₹14 Cr |
| FY20 | ₹74 Cr | ₹93 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 70.88%
- Foreign institutions: 1.25%
- Domestic institutions: 0.05%
- Non-institutions: 27.81%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Dishman Pharma](https://app.pivotnow.in/stock/DPC02) | — | ₹2,676 Cr | — | — |
| [Hikal](https://app.pivotnow.in/stock/HIKAL) | ₹217.00 | ₹2,676 Cr | — | — |
| [Dr Agarwals Eye Hospital](https://app.pivotnow.in/stock/DRAGARWQ) | ₹5,083.50 | ₹2,457 Cr | — | — |
| [Venus Remedies](https://app.pivotnow.in/stock/VENUSREM) | ₹1,796.10 | ₹2,401 Cr | 23.3 | — |
| [Fredun Pharmace](https://app.pivotnow.in/stock/FREDUN) | ₹1,435.00 | ₹2,373 Cr | 23.4 | — |
| [Dishman Carbogen Amcis](https://app.pivotnow.in/stock/DCAL) | ₹146.03 | ₹2,290 Cr | 23.5 | — |

## Questions and answers

### What is the share price of Alembic today?

Alembic (NSE: ALEMBICLTD) last closed at ₹92.50 on 21 Oct 2026. Its 52-week high is ₹117.72 and its 52-week low is ₹68.62.

### What is the market cap of Alembic?

Alembic's market capitalisation is ₹2,445 Cr (₹2,445 Cr) at the 19 Oct 2026 close, ranking 1068th among the NSE companies Pivot tracks.

### What is the P/E ratio of Alembic?

Alembic trades at a trailing P/E of 7.7. The median P/E of the 3 closest Pharma & Healthcare peers by market cap is 23.4.

### What is the ROE and ROCE of Alembic?

Return on equity was 13.0% in FY26 and return on capital employed was 6.1% in FY26 (consolidated figures).

### Is Alembic a debt-free company?

Alembic is close to debt-free: its debt-to-equity ratio was 0 in FY26.

### What were Alembic's latest quarterly results?

For Q4 FY26 (quarter ended 31 Mar 2026), Alembic reported revenue of ₹150 Cr, +10.6% year on year, and net profit of ₹16 Cr, +6.7% year on year.

### How has Alembic stock performed over the last year?

Alembic's share price has fallen 2.8% over the past year, +8.0% over three months and −6.9% over one month, to the 19 Oct 2026 close.

### What is the shareholding pattern of Alembic?

As of 30 Jun 2026: promoters 70.88%, foreign institutions 1.25%, domestic institutions 0.05%, non-institutions 27.81%.

### Who are Alembic's competitors?

The listed Pharma & Healthcare companies closest to Alembic by market cap are Dishman Pharma, Hikal, Dr Agarwals Eye Hospital, Venus Remedies, Fredun Pharmace and Dishman Carbogen Amcis.

### Is Alembic a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Alembic's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on ALEMBICLTD against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.